{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"108-088-660-176-665","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"108-088-660-176-665"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":10786,"type":"PATENT","title":"McGill University - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":4042,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8256,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: \"McGill univ*\";
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 3212
Search Applicants and Owners separately: \"McGill univ*\";
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 3212
a) V1 is a recombinant vector comprising the nucleic acid of SEQ ID NO:1 or a nucleic acid capable of hybridizing to SEQ ID NO:1 under stringent conditions.
b) V2 is a recombinant vector comprising the nucleic acid of SEQ ID NO:5 or a nucleic acid capable of hybridizing to SEQ ID NO:5 under stringent conditions.
c) V3 is a recombinant vector comprising the nucleic acid of SEQ ID NO:3 or a nucleic acid capable of hybridizing to SEQ ID NO:3 under stringent conditions.
d) V4 is a recombinant vector comprising the nucleic acid of SEQ ID NO:7 or a nucleic acid capable of hybridizing to SEQ ID NO:7 under stringent conditions."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["A host cell comprising the recombinant vector of claim 13."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["A host cell comprising two recombinant vectors as defined in claim 15 and which are expression vectors."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["A process for producing a cell, which produces the individual components of the heteromultimeric channel of claim 1, claim 2, or claim 3, including transforming or transfecting a host cell with the recombinant vector of claim 13 or the recombinant vectors defined in claim 17, such that the host cell, under appropriate culture conditions, produces the heteromultimeric channel complex of claim 1, claim 2, or claim 3."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["An antibody immunospecific for the protein complex of claim 1, claim 2, or claim 3."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["An antibody immunospecific for a domain of one of the components of the protein complex of claim 1, or claim 2, and said domain being involved in the interaction between said components."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["An antibody immunospecific for ASIC2A polypeptides of SEQ ID NO:2 or SEQ ID NO:6, which antibody is capable of inhibiting, preventing or disrupting the assembly of the individual components of the protein complex of claim 1, claim 2, or claim 3."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["An antibody immunospecific for ASIC3 polypeptides of SEQ ID NO:4 or SEQ ID NO:8, which antibody is capable of inhibiting, preventing or disrupting the assembly of the individual components of the protein complex of claim 1, claim 2, or claim 3."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["A hybridoma producing an antibody as defined in claims 19, 20, 21, or 22."],"number":23,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a subject in need of enhanced activity or expression of the heteromultimeric channel complex of claim 1, claim 2 or claim 3, comprising:
(a) administering to the subject a therapeutically effective amount of an agonist to said heteromultimeric channel; and/or
(b) providing to the subject a polynucleotide of claim 4, 5, 6, or 7 in a form so as to effect production of said heteromultimeric channel complex activity in vivo.
(c) providing to the subject a polynucleotide of SEQ ID NO: 1 and/or SEQ ID NO: 3 in a form so as to effect production of said heteromultimeric channel complex activity in vivo."],"number":24,"annotation":false,"title":false,"claim":true},{"lines":["A method for the treatment of a subject having need to inhibit activity or expression of the heteromultimeric channel complex of claim 1, claim 2 or claim 3, comprising:
(a) administering to the subject a therapeutically effective amount of an antagonist to said heteromultimeric channel; and/or
(b) administering to the subject a nucleic acid molecule that inhibits the expression of the nucleotide sequence encoding an essential component of said heteromultimeric channel; and/or
(c) administering to the subject a therapeutically effective amount of a polypeptide that competes with said heteromultimeric channel for its ligand.
(d) administering to the subject a therapeutically effective amount of a substance that inhibits, prevents and/or disrupts the assembly of the individual components comprising said heteromultimeric channel."],"number":25,"annotation":false,"title":false,"claim":true},{"lines":["A process for diagnosing a disease or a susceptibility to a disease in a subject related to the expression or activity of the heteromultimeric channel of claim 1, claim 2 or claim 3 in a subject, comprising:
(a) determining the presence or absence of a mutation in the nucleotide sequence encoding a component of said heteromultimeric channel in the genome of said subject; and/or
(b) analyzing for the presence or amount of heteromultimeric protein complex expression in a sample derived from said subject"],"number":26,"annotation":false,"title":false,"claim":true},{"lines":["A method for screening for agonists of the heteromultimeric channel of claim 1, claim 2, or claim 3, comprising:
(a) putting cells produced by claim 16 or claim 17 in contact with candidate compound(s); and
(b) determining whether a candidate compound induces or modulates a biological activity transduced by said heteromultimeric channel complex; or
c) determining whether a candidate compound induces inward currents or modulates proton-induced inward currents transduced by said heteromultimeric channel complex."],"number":27,"annotation":false,"title":false,"claim":true},{"lines":["An agonist identified by the method of claim 27."],"number":28,"annotation":false,"title":false,"claim":true},{"lines":["An agonist of claim 28, which is, or is an adjuvant to, an antidepressant, a desensibilising agent, an antipruritic, an analgesic (e.g by neurodegeneration of trigeminal neurons), a chemotherapeutic/ antineoplastic agent, an antiparkinsonian agent, a nigro-strial stimulant, an antipsychotic, a psychotherapeutic agent, a respiratory and cerebral stimulant, a cognitive stimulant, memory stimulant, a promoter of neuronal regeneration, a stimulant of cell growth and/or proliferation, an insecticide, a pesticide and/or an anthelmintic, or any combination thereof."],"number":29,"annotation":false,"title":false,"claim":true},{"lines":["The method for screening for antagonists of the heteromultimeric channel of claim 1, claim 2, or claim 3, comprising:
(a) putting cells produced by claim 16 or claim 17 in contact with a low pH solution (pH< 7.4) or any other agonist, including agonist of claim 28, and
(b) determing whether the signal generated by protons and/or said agonist is modulated, diminished or abolished in the presence of candidate compound(s)."],"number":30,"annotation":false,"title":false,"claim":true},{"lines":["An antagonist identified by the method of claim 30."],"number":31,"annotation":false,"title":false,"claim":true},{"lines":["An antagonist of claim 31, which is, or is an adjuvant to, an analgesic, an antipyretic, an antipruritic, an anxiolytic, sedative or hypnotic, a psychotherapeutic agent, an anticonvulsant, a neuroprotectant (e.g against central and/or excitotoxicity, such as in ischemia, stroke...), a general and/or local anesthetic, a hypotensive agent, a muscle relaxant, an antidiarrhea agent, an antacid, or any combination thereof."],"number":32,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}